Loading...
Market
What will be the acquisition price for Intra-Cellular Therapies by Johnson & Johnson?
3
Resolution / Starting Odds
Less than $12 billion • 25%
$12 billion to $14 billion • 25%
More than $14 billion • 25%
No acquisition announced • 25%
Official press releases from Johnson & Johnson or Intra-Cellular Therapies, major financial news outlets
Story
Johnson & Johnson Eyes $14 Billion Deal for Intra-Cellular Therapies, Valued at $10 Billion
Jan 12, 2025, 10:12 PM
Johnson & Johnson is exploring a potential acquisition of Intra-Cellular Therapies, a biopharmaceutical company focused on treatments for central nervous system disorders. The move could represent the largest biotech deal in over a year, with Intra-Cellular's market capitalization standing at approximately $10 billion following a recent jump. The discussions are ongoing, and no deal is certain, but the acquisition could break the drought of major biotech deals in 2024. The interest in Intra-Cellular comes after the company resolved an intellectual property overhang on Friday, potentially paving the way for this deal. If completed, the transaction is estimated to be valued at around $14 billion, which would be considered a fair price post-IP settlement.
View original story
Similar markets
Other Outcomes • 25%
Acquisition Delayed • 25%
Acquisition Abandoned • 25%
Acquisition Completed • 25%
Increase by more than 10% • 25%
Decrease • 25%
No significant change • 25%
Increase by 5-10% • 25%
No • 50%
Yes • 50%
More than $132 • 25%
Deal not completed • 25%
$132 • 25%
Less than $132 • 25%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
Increase by 0-10% • 25%
Increase by more than 10% • 25%
Decrease • 25%
No change • 25%
Yes • 50%
No • 50%